Search

Athena F Spanoyannis

from Ashburn, VA
Age ~59
Get Report
Also known as:
Athena F S Dutton, Athena F Dutton, Athena S Dutton, Athena D
Related to:
Eldon Livingston, 83Jody P Ronanyne, 52Dorene Boyle, 71Tamara Cozart, 32Nancy Dutton, 82
Connected to:
Katherine G Spansel, 41Megan R Spansel, 34Beth A Spanski, 60Jessica Spanswick, 50Allison K Spantgos, 35Suzanne A Spantgos, 58Betty B Spanton, 91Bob D Spanton, 62Matt Spanulo, 73Lawrence M Spanyer, 67

Athena Spanoyannis Phones & Addresses

  • Ashburn, VA
  • Tustin, CA
  • Irvine, CA
  • Santa Ana, CA
  • Costa Mesa, CA

Resumes

Resumes

Athena Spanoyannis Photo 1

Athena Spanoyannis

View page

Publications

Us Patents

Post-Translational Modifications And Clostridial Neurotoxins

View page
US Patent:
7223577, May 29, 2007
Filed:
May 31, 2005
Appl. No.:
11/141513
Inventors:
Lance E. Steward - Irvine CA, US
Ester Fernandez-Salas - Fullerton CA, US
Athena Spanoyannis - Ashburn VA, US
K. Roger Aoki - Coto de Caza CA, US
Wei-Jen Lin - Cerritos CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
C12N 9/00
C07K 1/00
US Classification:
435183, 530350
Abstract:
The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.

Post-Translation Modification And Clostridial Neurotoxins

View page
US Patent:
7888469, Feb 15, 2011
Filed:
Jan 17, 2007
Appl. No.:
11/624146
Inventors:
Lance E. Steward - Irvine CA, US
Ester Fernandez-Salas - Fullerton CA, US
Athena Spanoyannis - Ashburn VA, US
K. Roger Aoki - Coto de Caza CA, US
Wei-Jen Lin - Cerritos CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 39/00
C07K 1/00
US Classification:
530350, 4241851
Abstract:
The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.

Post-Translational Modifications And Clostridial Neurotoxins

View page
US Patent:
7893202, Feb 22, 2011
Filed:
Jan 17, 2007
Appl. No.:
11/624111
Inventors:
Lance E. Steward - Irvine CA, US
Ester Fernandez-Salas - Fullerton CA, US
Athena Spanoyannis - Ashburn VA, US
K. Roger Aoki - Coto de Caza CA, US
Wei-Jen Lin - Cerritos CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 39/00
C07K 1/00
US Classification:
530350, 4241851
Abstract:
The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.

Post-Translational Modifications And Clostridial Neurotoxins

View page
US Patent:
8119767, Feb 21, 2012
Filed:
Jan 17, 2007
Appl. No.:
11/624132
Inventors:
Lance E. Steward - Irvine CA, US
Ester Fernandez-Salas - Fullerton CA, US
Athena Spanoyannis - Ashburn VA, US
K. Roger Aoki - Coto de Caza CA, US
Wei-Jen Lin - Cerritos CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 39/00
C07K 1/00
US Classification:
530350, 4241841
Abstract:
The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.

Modified Clostridial Neurotoxins With Altered Biological Persistence

View page
US Patent:
20020127247, Sep 12, 2002
Filed:
Oct 31, 2001
Appl. No.:
10/004230
Inventors:
Lance Steward - Irvine CA, US
Athena Spanoyannis - Tustin CA, US
Kei Aoki - Coto De Caza CA, US
Wei-Jen Lin - Cerritos CA, US
Assignee:
Allergen Sales, Inc.
International Classification:
A61K039/08
C12P021/02
C07K014/33
US Classification:
424/239100, 530/350000, 435/069300
Abstract:
The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.

Botulinum Toxin Antibody Detection Assay

View page
US Patent:
57311617, Mar 24, 1998
Filed:
Apr 24, 1995
Appl. No.:
8/426796
Inventors:
Kei Roger Aoki - Laguna Hill CA
Athena Faye Spanoyannis - Tustin CA
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
G01N 3353
US Classification:
435 732
Abstract:
An assay for the identification of neutralizing botulinum antibodies in sera is provided which includes the steps of separating non-sodium dodecyl sulfate, non-trypsinized complex botulinum toxin in an arylamide gel by electrophoresis, the separation occurring on a basis of botulinum toxin protein size and charge. Thereafter, the separated protein is electrophoretically transferred onto a solid support, the transferred separated protein being bound to the solid support at spaced apart sites. Remaining sites on the solid support not occupied by bound protein are blocked and the solid support and bound protein are contacted with a sera sample containing an antibody directed against botulinum toxin. The contacted solid support is then exposed to a second antibody capable of reacting to produce an insoluble colored substrate of intensity relative to a quantity of antibodies present. Finally, the second antibody is reacted to produce the insoluble colored substrate which is visually identified.

Assay For Detecting The Presence Of Botulinum Toxin Neutralizing Antibodies In A Patient Serum Sample

View page
US Patent:
61365513, Oct 24, 2000
Filed:
Mar 17, 1998
Appl. No.:
9/044194
Inventors:
Kei Roger Aoki - Laguna Hills CA
Athena F. Spanoyannis - Tustin CA
Assignee:
ALLERGAN, Inc. - Irvine CA
International Classification:
G01N 3353
G01N 33561
G01N 33544
A61K 3902
C12Q 170
US Classification:
435 732
Abstract:
An assay for the identification of neutralizing botulinum antibodies in sera is provided which includes the steps of separating non-sodium dodecyl sulfate, non-trypsinized complex botulinum toxin in an arylamide gel by electrophoresis, the separation occurring on a basis of botulinum toxin protein size and charge. Thereafter, the separated protein is electrophoretically transferred onto a solid support, the transferred separated protein being bound to the solid support at spaced apart sites. Remaining sites on the solid support not occupied by bound protein are blocked and the solid support and bound protein are contacted with a sera sample containing an antibody directed against botulinum toxin. The contacted solid support is then exposed to a second antibody capable of reacting to produce an insoluble colored substrate of intensity relative to a quantity of antibodies present. Finally, the second antibody is reacted to produce the insoluble colored substrate which is visually identified.
Control profile
Athena F Spanoyannis from Ashburn, VA, age ~59 Get Report